Cagrilintide
Also known as: AM833 · CagriSema component
Cagrilintide is Novo Nordisk's long-acting amylin / calcitonin receptor agonist, in Phase 3 (mostly via CagriSema, the combination with semaglutide). Different mechanism from GLP-1 / GIP; complementary rather than redundant. Not yet approved.
Last reviewed · Panya.health editorial
Panya scores vendors against an 11-signal rubric. Vendors at or above 70 out of 100 are routable; below 70 are documented but get no Panya affiliate link. For prescription peptides like Mounjaro and Wegovy, Panya routes today through licensed clinicians. For research peptides like Cagrilintide, vendor scorecards land in a follow-up sprint after legal review and payment processor selection. Until then, the page surfaces commonly-mentioned vendor names so adults can do their own diligence. We do not yet earn commission on any Cagrilintide vendor.
Not medical advice. Cagrilintide is not approved for human medical use in most jurisdictions. The data below is what users do; it is not what regulators have validated. You decide your risk profile.
What it does, and how
Cagrilintide is a long-acting, lipidated synthetic analog of amylin (a peptide co-secreted with insulin from pancreatic beta cells). It binds amylin receptors and calcitonin receptors, slowing gastric emptying and amplifying satiety signaling via the area postrema in the brainstem. Mechanism is genuinely complementary to GLP-1 / GIP receptor agonism: gastric-emptying delay overlaps but the central satiety pathway is distinct, which is the rationale for combining cagrilintide with semaglutide as CagriSema. The lipidation (fatty acid attached to enable albumin binding) gives a half-life supporting once-weekly subcutaneous dosing, mirroring the dose schedule of semaglutide and tirzepatide. Novo Nordisk's Phase 3 REDEFINE program tests CagriSema in obesity and T2D. The 2024 REDEFINE-1 readout showed approximately 22.7% mean weight loss at 2.4 mg cagrilintide + 2.4 mg semaglutide weekly over 68 weeks. That number was below pre-trial market expectations (>25%), which moved Novo's stock and triggered re-evaluation of the combination's competitive position vs Lilly's tirzepatide and retatrutide programs.
Typical practice
Trial dose: 2.4 mg subcutaneous weekly (cagrilintide alone); CagriSema combines this with 2.4 mg semaglutide weekly. Escalation typical: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg over 16 weeks, mirroring semaglutide's titration schedule for tolerability. Research-chem cagrilintide is sold but is rare compared to tirzepatide because the molecule is harder to synthesize (the lipidation chemistry is non-trivial) and the supply chain less mature. Reconstitution: standard subcutaneous protocol; typical research-chem vial 5 mg in 1.5 mL bacteriostatic water for ~3.3 mg/mL concentration. The calculator at panya.health/tools/reconstitution-calculator handles the math.
The dosing above is community practice, not a regulator-validated protocol. Trial-validated dosing for Cagrilintide in humans does not exist for most use cases listed.
Risks and contraindications
Phase 3 GI side effects (nausea, vomiting, diarrhea) tracked similar dose-response curves to GLP-1 trials. The amylin-specific pattern is slightly different: less acute nausea-on-injection, more prolonged early satiety. Heart rate elevation similar to GLP-1 class. The thyroid C-cell tumor concern (which carries a black-box warning on liraglutide, semaglutide, tirzepatide based on rat-model data) extends to amylin analogs by mechanism similarity; Phase 3 monitoring is set up for this. Pre-existing T2D with poor glycemic control, gastroparesis, history of medullary thyroid carcinoma or MEN-2 are class-level contraindications. Pregnancy and breastfeeding off-limits. The case for waiting for Phase 3 readouts and approval is stronger for cagrilintide than for tirzepatide because we have less long-term human data; research-chem use carries the same supply-chain quality concerns as for retatrutide.
Where this stands legally
Not FDA-approved. Novo's CagriSema is in Phase 3; readouts for the obesity indication continued through 2024-2025. Clinical trial enrollment is the legitimate access route. Research-chem channel exists but supply is thinner than for tirzepatide.
MHRA has not approved cagrilintide. Some UK clinical trial sites participating in REDEFINE / CagriSema Phase 3.
EMA has not approved cagrilintide. Novo runs Phase 3 sites in Denmark and other EU countries; trial enrollment is the legitimate path.
TGA Schedule 4 by default for unapproved peptides. Trial enrollment via Novo sites is the route.
Not approved. Trial sites operate at Bangkok hospitals participating in Novo Phase 3. Research-chem channels available but cagrilintide is less commonly stocked than tirzepatide.
MOHAP has not approved cagrilintide. Personal-use imports of unapproved peptides are commonly held at customs.
Where users say they source it
Names below are sourced from community discussion. None are currently scored against the Panya 11-signal rubric. Panya does not earn commission on any of these. You can search them yourself; treat the list as a starting point for your own diligence, not an endorsement.
- Novo Nordisk clinical trial enrollment (the legitimate route)Pending Panya 11-signal audit
- Pure RawzPending Panya 11-signal audit
- Limitless LifePending Panya 11-signal audit
- AminolabsPending Panya 11-signal audit
Full vendor scorecards for Cagrilintide land in a follow-up sprint after lawyer review and payment processor selection. We will not route users to any vendor that scores below 70 on the rubric.
Papers worth reading directly
- Lau et al. — Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet, 2021 →
- Enebo et al. — Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg in adults with overweight and obesity. Lancet, 2021 →
- ClinicalTrials.gov — REDEFINE-1 (CagriSema in Adults with Overweight or Obesity, Phase 3, NCT05567796) →
- Novo Nordisk REDEFINE-1 results announcement, 2024 (CagriSema 22.7% weight loss vs semaglutide 16.1% vs cagrilintide 11.8% vs placebo) →
People asking adjacent questions
On the 2024 REDEFINE-1 readout: no, not meaningfully better. CagriSema produced 22.7% mean weight loss at 68 weeks, similar to tirzepatide's SURMOUNT-1 (22.5% at 72 weeks). The pre...
Different mechanism, different feel. Tesofensine is a triple monoamine reuptake inhibitor with Astrup 2008 Phase 3 data of ~11% weight loss at 1 mg over 24 weeks. Feels closer to a...
For most weight-loss patients, Mounjaro (tirzepatide) is the better first choice if you can get it: higher average loss, similar tolerability. Wegovy (semaglutide) wins on three sp...
Panya blog posts
Tirzepatide monthly cost across 10 markets: US brand, US compounded, UK private, Scandinavia, Germany, Thailand clinic, Thailand direct, Japan, Singapore, Australia. The real numbe...
The phrase on every grey-market peptide site. What it actually means, what it does not mean, and why reading it wrong costs people money.
Adjacent reading
Track Cagrilintide in your peptide journal.
Panya users log their full stack at panya.health/journey. Public-by-default with per-entry privacy controls. Vote-validated by the community.